BMO Capital analyst, Alex Arfaei, reiterated his Outperform rating on shares of Merck (NYSE: MRK) but cut his price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change